Latest Breaking News On - வாழ்க்கை இழந்தது - Page 6 : comparemela.com
Corona kostet bisher mehr als 300 000 Lebensjahre in Deutschland
faz.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from faz.net Daily Mail and Mail on Sunday newspapers.
Coronavirus-Liveticker: +++ 23:26 Rund 4700 US-Soldaten sollen Impfkampagne unterstützen +++
n-tv.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from n-tv.de Daily Mail and Mail on Sunday newspapers.
Coronavirus-Liveticker: +++ 22:23 Seuchenbehörde befürwortet Öffnung der Schulen in den USA +++
n-tv.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from n-tv.de Daily Mail and Mail on Sunday newspapers.
relapsed or refractory chronic lymphocytic leukaemia progression after 12 months vs. 68% for comparators AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.
against ibrutinib in chronic lymphocytic leukaemia Superior safety on key secondary endpoint of atrial fibrillation Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib. The trial also met a key secondary endpoint for safety, showing patients treated with Calquence had statistically significantly lower incidence of atrial fibrillation compared to patients treated with ibrutinib. Atrial fibrillation is an irregular heart rate that can increase the risk of stroke, heart failure and other heart-related complications .
1 Further hierarchical testing revealed no difference for Grade 3 or higher infections or Richter s transformation. There was a descriptive trend for numerically fa